Search Results

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec) Over Five Years

https://www.cslbehring.de/en-us/news/2025/pm-hemgenix-long-term-durability-safety

First Patient Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Haemophilia B in Germany

https://www.cslbehring.de/en-us/news/2025/pm-hemgenix-erster-patient-deu

First Patient Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Haemophilia B in Austria

https://www.cslbehring.de/news/2025/pm-hemgenix-first-patient-at

First patients treated with HEMGENIX® (etranacogene dezaparvovec) gene therapy for haemophilia B in Denmark

https://www.cslbehring.de/news/2025/pm-hemgenix-first-patients-denmark

Get to know us and learn more about people, projects and what happens in the world of CSL Behring.

https://www.cslbehring.de/en-us/news/2023

CSL Behring Signs Milestone Commercial Agreement with Amgros to Fund Haemophilia B Gene Therapy HEMGENIX® in Denmark

https://www.cslbehring.de/en-us/news/2024/pm-agreement-amgros-denmark

Get to know us and learn more about people, projects and what happens in the world of CSL Behring.

https://www.cslbehring.de/en-us/news/2021

CSL Behring granted positive reimbursement recommendation for Haemophilia B Gene Therapy, HEMGENIX® in Spain

https://www.cslbehring.de/en-us/news/2024/pm-hmgenix-reimbursement-spain

Information on the terms and conditions of use of the CSL Behring Germany website.

https://www.cslbehring.de/en-us/terms-of-use

Lernen Sie uns kennen und erfahren Sie mehr über Menschen, Projekte und was in der Welt von CSL Behring passiert.

https://www.cslbehring.de/news/2025